STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Hutchmed (China) Limited SEC Filings

HCM Nasdaq

Welcome to our dedicated page for Hutchmed (China) SEC filings (Ticker: HCM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Finding the next trial milestone or royalty clause inside HUTCHMED’s labyrinth of biotech disclosures can feel impossible. If you have ever typed “HUTCHMED SEC filings explained simply” or hunted down a single R&D footnote in a 300-page report, you know the challenge.

Stock Titan solves it. Our AI reviews every submission the moment it hits EDGAR, then surfaces what matters—so you can read an entire HUTCHMED annual report 10-K simplified in minutes, not hours. Need the latest HUTCHMED quarterly earnings report 10-Q filing or a fast HUTCHMED earnings report filing analysis? They’re here, paired with plain-English summaries and side-by-side financial trends. Wondering about management deals? We stream HUTCHMED Form 4 insider transactions real-time and flag unusual HUTCHMED executive stock transactions Form 4 before the market reacts.

Use the platform to:

  • Track HUTCHMED insider trading Form 4 transactions instantly
  • Spot trial updates inside every 8-K with HUTCHMED 8-K material events explained
  • Compare pay packages in the latest HUTCHMED proxy statement executive compensation
  • Speed-read complex risk factors by understanding HUTCHMED SEC documents with AI

Whether you follow oncology catalysts, cash runway, or manufacturing scale-ups, our real-time alerts, expert commentary, and AI-powered summaries keep you ahead of the curve—so you make decisions with confidence instead of skimming PDFs at midnight.

Rhea-AI Summary

HUTCHMED (CHINA) LIMITED filed a Form 6-K furnishing Exhibit 99.1, a press release about completion of enrollment in the SAFFRON global phase III trial evaluating the combination of ORPATHYS and TAGRISSO for certain lung cancer patients with MET overexpression and/or amplification after progression on TAGRISSO.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.82%
Tags
current report
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report

FAQ

What is the current stock price of Hutchmed (China) (HCM)?

The current stock price of Hutchmed (China) (HCM) is $14.35 as of December 1, 2025.

What is the market cap of Hutchmed (China) (HCM)?

The market cap of Hutchmed (China) (HCM) is approximately 2.5B.
Hutchmed (China) Limited

Nasdaq:HCM

HCM Rankings

HCM Stock Data

2.48B
174.22M
0.13%
3.63%
0.23%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
Hong Kong
CAMBRIDGE